NeuroMab™ Anti-Amyloid Beta 1-42 BBB Shuttle Antibody(NRZP-1022-ZP3654)

Figure 1 depicts the immunoprecipitation of peroxynitrite-treated oligomeric Aβ1-42 preparations precipitated with various Aβ antibodies (3D6, 6C6, 12A11, 12B4, 3A3, 266, 9G8, 15C11, and 6H9) and imaged with 3D6 Western blot of the object. Approximate positions of Aβ1-42 monomer, dimer, trimer, and tetramer bands are shown on the left side of the Figure. Indicated below each Aβ antibody are the Aβ epitopes recognized by the antibody and the results of contextual fear conditioning (CFC) assays for the antibody, with a "+" sign indicating an increase in cognition observed after treatment with the antibody and a "-" sign indicating an increase observed with No change in cognition after antibody treatment, "+/-" sign indicates that a trend towards increased cognition was observed after antibody treatment, but the observed trend was not statistically significant enough to indicate an observed increase in cognition cognition , the "ND" symbol indicates that there is no CFC assay data for comparison for this antibody.

Figure 2 depicts proteins from immunoprecipitates of peroxynitrite-treated oligomeric Aβ1-42 preparations precipitated with various Aβ antibodies (3D6, 6C6, 12A11, 12B4, 10D5, 3A3, 266, and 6H9) and imaged with 3D6 blot. Notes are the same as in Figure 3.

Figure 3 depicts the results of a study in which a single dose of 12A11 (1 mg/kg) in mice was assessed for cognitive Improved duration of time (CFC) assay.